ChemoCentryx Inc (NASDAQ:CCXI) gets downgraded to Neutral by JPMorgan Chase & Co.

ME Staff
-
0

Analyst Ratings For ChemoCentryx Inc (NASDAQ:CCXI)

Today, ChemoCentryx Inc (NASDAQ:CCXI) stock was downgraded by JPMorgan Chase & Co. from Overweight to Neutral.

There are 2 Hold Ratings, 2 Buy Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on ChemoCentryx Inc (NASDAQ:CCXI) is Buy with a consensus target price of $18.00 per share, a potential 42.07% upside.

Some recent analyst ratings include

  • 8/14/2018-ChemoCentryx Inc (NASDAQ:CCXI) gets downgraded to Neutral by JPMorgan Chase & Co.
  • 8/13/2018-ChemoCentryx Inc (NASDAQ:CCXI) had its Buy rating reiterated by HC Wainwright with a $20.00 price target
  • 8/10/2018-ChemoCentryx Inc (NASDAQ:CCXI) had its Buy rating reiterated by Canaccord Genuity with a $18.00 price target
  • 6/28/2018-ChemoCentryx Inc (NASDAQ:CCXI) has coverage initiated with a Strong-Buy rating and $18.00 price target
  • 5/10/2018-ChemoCentryx Inc (NASDAQ:CCXI) had its Hold rating reiterated by Cowen
  • 2/21/2017-ChemoCentryx Inc (NASDAQ:CCXI) has coverage initiated with a Mkt Outperform ➝ Outperform rating

Recent Insider Trading Activity For ChemoCentryx Inc (NASDAQ:CCXI)
ChemoCentryx Inc (NASDAQ:CCXI) has insider ownership of 14.50% and institutional ownership of 51.11%.

  • On 6/29/2018 Markus J Cappel, Insider, sold 25,179 with an average share price of $13.67 per share and the total transaction amounting to $344,196.93.
  • On 6/29/2018 Thomas J Schall, CEO, sold 100 with an average share price of $14.10 per share and the total transaction amounting to $1,410.00.
  • On 6/28/2018 Susan M Kanaya, CFO, sold 49,507 with an average share price of $13.79 per share and the total transaction amounting to $682,701.53.
  • On 6/27/2018 Markus J Cappel, Treasurer, sold 800 with an average share price of $13.50 per share and the total transaction amounting to $10,800.00.
  • On 6/26/2018 Susan M Kanaya, CFO, sold 850 with an average share price of $13.25 per share and the total transaction amounting to $11,262.50.
  • On 5/23/2018 Thomas J Schall, Insider, sold 92,798 with an average share price of $12.84 per share and the total transaction amounting to $1,191,526.32.
  • On 5/21/2018 Markus J Cappel, Insider, sold 2,709 with an average share price of $13.00 per share and the total transaction amounting to $35,217.00.

About ChemoCentryx Inc (NASDAQ:CCXI)
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

Recent Trading Activity for ChemoCentryx Inc (NASDAQ:CCXI)
Shares of ChemoCentryx Inc closed the previous trading session at 12,67 +0,72 6,03 % with 185900 shares trading hands.